STAT1 and COVID-19: After the identification of increased EGFR expression in COVID-19 patients, induced by lung injury and STAT1 deficit, first studies now also suggest that the usage of a specific EGFR antibody could reduce inflammation and fibrosis in severe and moderate COVID-19 patients (Londres et al, 2022).